中国医药
中國醫藥
중국의약
CHINA MEDICINE
2013年
9期
1204-1205
,共2页
卢英霞%刘丽军%信栓力%常超%张兰华%马燕霞%裴利敏%刘桂兰%王晓丽
盧英霞%劉麗軍%信栓力%常超%張蘭華%馬燕霞%裴利敏%劉桂蘭%王曉麗
로영하%류려군%신전력%상초%장란화%마연하%배리민%류계란%왕효려
心绞痛,不稳定型%血脂康%基质金属蛋白酶9%肿瘤坏死因子α
心絞痛,不穩定型%血脂康%基質金屬蛋白酶9%腫瘤壞死因子α
심교통,불은정형%혈지강%기질금속단백매9%종류배사인자α
Angina,unstable%Xuezhikang%Matrix metalloproteinase 9%Tumor necrosis factor α
目的 研究血脂康对不稳定型心绞痛(UAP)患者血浆基质金属蛋白酶(MMP-9)和肿瘤坏死因子α(TNF-α)的影响,探讨其抗炎抗氧化治疗效果.方法 采用酶联免疫吸附测定(ELISA)法测定65例UAP患者(UAP组)服药持续时间前后(血脂康胶囊0.6 g/d,治疗1个月)及冠状动脉造影正常者(对照组,40例)血浆MMP-9及TNF-α浓度.结果 UAP组治疗前MMP-9、TNF-α血浆水平为(24±6) mg/L、(22±4) μg/L,与对照组[(20±6)mg/L和(16±4) μg/L]比较,差异有统计学意义(P＜0.01),服用血脂康4周后UAP组血浆MMP-9及TNF-α水平[分别为(21±6)mg/L和(19±4)μg/L]较治疗前明显下降(均P＜0.01).结论 血脂康在抑制UAP患者炎症反应、稳定动脉粥样斑块,减少急性心血管事件方面可能有一定的作用.
目的 研究血脂康對不穩定型心絞痛(UAP)患者血漿基質金屬蛋白酶(MMP-9)和腫瘤壞死因子α(TNF-α)的影響,探討其抗炎抗氧化治療效果.方法 採用酶聯免疫吸附測定(ELISA)法測定65例UAP患者(UAP組)服藥持續時間前後(血脂康膠囊0.6 g/d,治療1箇月)及冠狀動脈造影正常者(對照組,40例)血漿MMP-9及TNF-α濃度.結果 UAP組治療前MMP-9、TNF-α血漿水平為(24±6) mg/L、(22±4) μg/L,與對照組[(20±6)mg/L和(16±4) μg/L]比較,差異有統計學意義(P＜0.01),服用血脂康4週後UAP組血漿MMP-9及TNF-α水平[分彆為(21±6)mg/L和(19±4)μg/L]較治療前明顯下降(均P＜0.01).結論 血脂康在抑製UAP患者炎癥反應、穩定動脈粥樣斑塊,減少急性心血管事件方麵可能有一定的作用.
목적 연구혈지강대불은정형심교통(UAP)환자혈장기질금속단백매(MMP-9)화종류배사인자α(TNF-α)적영향,탐토기항염항양화치료효과.방법 채용매련면역흡부측정(ELISA)법측정65례UAP환자(UAP조)복약지속시간전후(혈지강효낭0.6 g/d,치료1개월)급관상동맥조영정상자(대조조,40례)혈장MMP-9급TNF-α농도.결과 UAP조치료전MMP-9、TNF-α혈장수평위(24±6) mg/L、(22±4) μg/L,여대조조[(20±6)mg/L화(16±4) μg/L]비교,차이유통계학의의(P＜0.01),복용혈지강4주후UAP조혈장MMP-9급TNF-α수평[분별위(21±6)mg/L화(19±4)μg/L]교치료전명현하강(균P＜0.01).결론 혈지강재억제UAP환자염증반응、은정동맥죽양반괴,감소급성심혈관사건방면가능유일정적작용.
Objective To explore the anti-infammatory and antioxidation effect of Xuezhikang on patients with unstable angina pectoris control group (40 cases).Methods Plasma matrix metalloproteinase 9 (MMP-9),tumor necrosis factor α(TNF-α) were detected by enzyme linked immunosorbent assay(ELISA) 4 weeks before and after oral administration of xuezhikang in 60 patients with unstable angina pectoris and control group (40 cases).Results The levels of plasma MMP-9,TNF-α [(24 ± 6) mg/L,(22 ± 4) μg/L] in patients with UAP group were significantly increased compared with those of control group [(20 ± 6) mg/L,(16 ± 4) μg/L] (P ＜ 0.01).A significant decreased plasma MMP-9,TNF-α were observed 4 weeks after Xuezhikang-taken[(21 ± 6)mg/L vs (24 ±6] mg/L,(19 ± 4) μg/L vs (22 ± 4) μg/L] (P ＜ 0.01).Conclusion Xuezhikang can have good anti-inflammatory and antioxidation and good prognosis in patients with unstable andgina pectoris.
